drugset / Trial / NCT01361412
Identification of Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy
Phase 2
Completed
20 enrolled
Circassia Limited
Adiga Life Sciences, Inc. · collabCetero Research, San Antonio · collab
RandomizedParallel-groupDouble-blind
Summary
The aim of the study is to identify changes in potential biomarkers after peptide immunotherapy for that may subsequently be developed as biomarkers that correlate with clinical efficacy.
Timeline
- Start
- 2011-03
- Primary completion
- 2011-09
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ToleroMune Ragweed | Vaccine | — | Other |